INOVIO PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $81.62M
- P/E (TTM)
- –
- Dividend yield
- –
About Inovio Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
INOVIO Pharmaceuticals is a clinical-stage biotechnology company that develops DNA medicines to treat and prevent human papillomavirus-associated diseases, cancer, and infectious diseases. Its core platform combines engineered circular DNA plasmids with proprietary CELLECTRA electroporation delivery devices to facilitate cellular uptake. The company's lead candidate is INO-3107 for recurrent respiratory papillomatosis, alongside pipeline assets including INO-3112 for throat cancer and INO-5401 for glioblastoma. Because all drug candidates remain in development without commercial sales, the company does not have commercial consumers. Instead, it works with research partners, corporate collaborators, and government entities.
The company conducts global clinical trials across the United States, Europe, and China. Its drug candidates have been administered more than 19,000 times across nearly 6,000 study participants. In Europe, the business maintains CE-mark certification for its CELLECTRA 5PSP delivery device. Partner organizations also conduct clinical testing in China. The provided text does not state the company's headquarters location.
Summary of the business section of Inovio Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- INOVIO PHARMACEUTICALS, INC.
- Founded
- 1983
- Headquarters
- Plymouth Meeting, PA
- Address
- 660 W. Germantown Pike, Suite 110 19462
- Phone
- (858) 410-3134
- Website
- www.inovio.com
- Employees
- 27, Dec 31, 2008
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst& YoungLLP, San Diego, California
Stock & identifiers
- Ticker
- INO
- Exchange
- Nasdaq
- IPO date
- Dec 8, 1998
- Shares outstanding
- 103M, Aug 10, 2026
- Public float
- $74.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Jan 25, 2024; 1-for-12 reverse, Jan 24, 2024; 1-for-4 reverse, Jun 6, 2014; 1-for-4 reverse, Jun 5, 2014; 1-for-4 reverse, Sep 13, 2004
- SEC CIK
- 1055726
- CUSIP
- 45773H409
- ISIN
- US45773H4092
- LEI
- 529900B9W875XDZXTM97
- EIN
- 33-0969592
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jacqueline Elizabeth Shea | Chief Executive Officer, Director | 111,021 |
| Peter Kies | CFO | 47,917 |
| Laurent Humeau | Chief Scientific Officer | 48,986 |
| Michael John Sumner | Chief Medical Officer | 42,038 |
| Lota S. Zoth | Director | 8,726 |
| Jay Shepard | Director | 9,209 |
| Roger D. Dansey | Director | 8,916 |
| Ann Calby Miller | Director | 9,877 |
| Simon X. Benito | Director | 12,191 |
| David B. Weiner | Director | 87,592 |
| Wendy L. Yarno | Director | 10,512 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Jacqueline E.Shea Ph.D | $1.59M | $1.46M | $872.16K | $9 | – |
| FY2024 Jacqueline E.Shea Ph.D | $2.05M | $904.04K | $988.74K | $10 | – |
| FY2023 Jacqueline E.Shea Ph.D | $2.44M | $1.15M | $1.15M | $33 | – |
| FY2022 J.Joseph Kim Ph.D | $10.47M | $3.42M | $1.59M | $31 | – |
| FY2022 Jacqueline E.Shea Ph.D | $3.52M | $1.79M | $1.59M | $31 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Corporate history
Events identified from SEC filings